ERBB2 and breast carcinoma: Although these studies have demonstrated a strong correlation between the 89Zr-trastuzumab PET/CT signal and the presence of HER2-positive breast cancer cells, the potential role of 89Zr-trastuzumab PET/CT in NAT response evaluation has not yet been investigated.